Can Megace Cause Blood Clots?
Yes, Megace (megestrol acetate) significantly increases the risk of blood clots and thromboembolic events, with approximately 1 in 6 patients developing thromboembolism during treatment.
Magnitude of Thrombotic Risk
The risk of blood clots with megestrol acetate is well-established across multiple high-quality guidelines and clinical studies:
In cancer cachexia patients, megestrol acetate increases thromboembolic events by 84% (RR 1.84; 95% CI, 1.07 to 3.18) compared to placebo 1.
The National Comprehensive Cancer Network reports that 1 in 6 patients (approximately 17%) treated with megestrol acetate will develop thromboembolic phenomena 1.
ASCO guidelines from 2020 confirm increased risks of death (RR 1.42), thromboembolic events (RR 1.84), and edema (RR 1.36) when using megestrol acetate for cancer cachexia 1.
Types of Thrombotic Events
The FDA drug label and postmarketing surveillance have documented multiple forms of venous thromboembolism associated with megestrol acetate 2:
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Thrombophlebitis
High-Risk Populations
Certain patient groups face particularly elevated thrombotic risk:
Nursing home residents: Multiple studies document DVT rates of 32% among nursing home patients treated with megestrol acetate, even in ambulatory individuals without other risk factors 3, 4.
Patients with sickle cell disease: Case reports demonstrate rapid potentiation of prothrombotic states within days of starting megestrol acetate, resulting in paradoxical embolism 5.
Patients on concurrent anticoagulation: Megestrol acetate may exert both prothrombotic and anticoagulant effects, creating unpredictable drug interactions with anticoagulants like rivaroxaban 6.
Cancer patients receiving chemotherapy: While thrombosis is common in oncology patients generally, the addition of megestrol acetate appears to compound this risk 7.
Clinical Implications and Monitoring
The ESPEN guidelines explicitly recommend considering progestins (including megestrol acetate) to increase appetite in anorectic cancer patients with advanced disease BUT emphasize awareness of potential serious side effects, specifically thromboembolism 1.
Key monitoring considerations include:
Use caution in patients with any history of thromboembolic disease 2.
The FDA drug label warns that megestrol acetate is "known to be substantially excreted by the kidney," and thrombotic risk may be greater in patients with impaired renal function 2.
Most thrombotic events occur after 50 days of treatment, though they can develop earlier 4.
Risk-Benefit Assessment
The decision to use megestrol acetate must weigh modest benefits against substantial risks:
While 1 in 4 patients experience increased appetite and 1 in 12 gain weight, 1 in 6 develop thromboembolism and 1 in 23 die 1.
For nursing home residents with weight loss, the efficacy of megestrol acetate is unproven, making the thrombotic risk particularly concerning 8, 4.
ASCO guidelines note that "evidence remains insufficient to strongly endorse any pharmacologic agent to improve cancer cachexia outcomes; clinicians may choose not to offer medications for the treatment of cancer cachexia" 1.
Common Pitfall to Avoid
Do not assume that megestrol acetate is safe simply because a patient is ambulatory or lacks traditional VTE risk factors. The nursing home studies demonstrate that DVT can occur even in ambulatory individuals with no other known risk factors 4. The drug itself appears to be an independent and potent risk factor for thromboembolism.